Summary
Calcium channel blockers (CCBs) inhibit voltagedependent L-type calcium channels. This leads to vascular smooth muscle relaxation and negative inotropic and chronotropic effects in the heart. The latter are counteracted in vivo by a vasodilatation-triggered, baroreceptor-mediated reflex increase in sympathetic tone, resulting in indirect cardiostimulation. The mean vascular/cardiac effect ratios of the first-generation CCBs—verapamil, nifedipine, and diltiazem—are relatively low and amount to approximately 3, 10, and 3, respectively. The pharmacokinetic properties of verapamil, nifedipine, and diltiazem are similar. The drugs are almost completely absorbed after oral administration, but their bioavailability is reduced because of first-pass hepatic metabolism. The onset of action of verapamil, nifedipine, and diltiazem, at least in immediate-release formulations, is relatively fast (0.5–2 hours), and their elimination half-lives range from 2 to 7 hours. The second-generation CCBs (e.g., amlodipine, felodipine, and nisoldipine) have a slower onset of action (due to either intrinsic properties of the drug or a slow-release formulation), a longer duration of action, and greater vascular/cardiac effect ratios. These features may provide therapeutic benefits, for example, a less pronounced increase in sympathetic tone and reflex tachycardia, and reduced likelihood of negative inotropic effects. These agents can therefore probably be used in patients with left ventricular dysfunction.
Similar content being viewed by others
References
Haas H, Härtfelder G. α-Isopropyl-α-[(N-methyl-N-homoveratryl)-r-amino-propyl]-3,4-dimethoxyphenylacetonitril, eine Substanz mit coronargefäßerweiternden Eigenschaften. Arzneimittelforschung 1962;12:549–558.
Fleckenstein A. History of calcium antagonists. Circ Res 1983;52(Suppl I):I3-I16.
Ruzicka M, Lennen FHH. Relevance of 24 hour blood pressure profile and sympathetic activity for outcome on shortversus long-acting 1,4-dihydropyridines. Am J Hypertens 1995;9:86–94.
Murdoch D, Brogden RN. Sustained release of nifedipine formulations. Drugs 1991;41:737–779.
Van Zwieten PA, Pfaffendorf M. Similarities and differences between calcium antagonists: Pharmacological aspects. J Hypertens 1993;11(Suppl 1):S3-S11.
Furberg CD, Psaty BM, Meyer JV. Nifedipine, doserelated increase in mortality in patients with coronary heart disease. Circulation 1995;92:1325–1331.
Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620–625.
Lüscher TF, Wenzel RR, Noll G. Calcium-Antagonisten in der Kontroverse: Gibt es eine rationale Differentialtherapie? Dtsch Med Wochenschr 1996;121:523–538.
Freedman DD, Waters DD. ‘Second generation’ dihydropyridine calcium antagonists. Drugs 1987;34:578–598.
Nayler WG, ed. Second Generation of Calcium Antagonists. Berlin: Springer, 1991.
Godfraind T, Salomone S, Dessy C, Verhelst B, Dion R, Schoevaerts JC. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol 1992;20(Suppl 5):S34-S41.
Kelly JG, O'Malley K. Clinical pharmaco-kinetics of calcium antagonists. Clin Pharmacokinet 1992;22:416–433.
Nayler WG, ed. Amlodipine. Berlin: Springer, 1993.
Hugenholtz PG, Meyer J, eds. Nisoldipine 1987. Berlin: Springer, 1987.
Lichtlen PR, Hugenholtz PG, eds. Recent Aspects in Calcium Antagonism: Nisoldipine. Stuttgart: Schattauer, 1988.
Rousseau MF, Melin J, Benedict CR, Ahn S, Raphael D, Bornemann M. Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction. Eur Heart J 1994; 15:957–964.
Rahimtoola SH, Remme WJ, eds. A symposium: Left ventricular dysfunction, calcium antagonism, and nisoldipine. Am J Cardiol 1995;75:1E–76E.
Zannad F. Clinical pharmacology of nisoldipine coat core. Am J Cardiol 1995;75:41E-45E.
Saltiel E, Ellrodt AG, Monk JP, Langley MS. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1988;36:387–428.
Blychert E, Hedner T, Dahlöf C, Elmfeld D. Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients. J Cardiovasc Pharmacol 1990;15:428–435.
Peruche B. Felodipin: Ein vasoselektiver Calciumantagonist. Pharm Ztg 1992;137:3821–3825.
O'Connor CM, Belkin RN, Carson PE, et al. for The PRAISE Investigators. Circulation 1995;92(Suppl I): I-143.
Cohn JN, Ziesche SM, Loss LE, Anderson GF, and the V-HeFT Study Group. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: Results of V-HeFT VIII. Circulation 1995; 92(Suppl I):I143.
The DEFIANT Research Group, Poole-Wilson PA. Doppler flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy. Results of the DEFIANT-II study. Eur Heart Jt 1997, in press.
Godfraind T. Cardioselectivity of calcium antagonists. Cardiovasc Drugs Ther 1994;8:353–364.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scholz, H. Pharmacological aspects of calcium channel blockers. Cardiovasc Drug Ther 10 (Suppl 3), 869–872 (1997). https://doi.org/10.1007/BF00051613
Issue Date:
DOI: https://doi.org/10.1007/BF00051613